Stanford University

education 📍 Stanford, United States
Stanford University
2
Lidocaine Infusion Publications
2
Lidocaine Infusion Researchers

Associated Institutions

VA Palo Alto Health Care System
related
Santa Clara Valley Medical Center
related
SLAC National Accelerator Laboratory
child
Kavli Institute for Particle Astrophysics and Cosmology
child
Chan Zuckerberg Biohub San Francisco
child

Publications

Analgesic efficacy and safety of lidocaine administered by intravenous route vs erector spinae plane blocks following open heart surgery: An open-label, randomized clinical trial.

Selvamani BJ, Sharma A, Farhat B, Sahin L, Seering MS , et al.
Journal of clinical anesthesia

The erector spinae plane (ESP) block is a widely used regional analgesic technique for truncal analgesia. This randomized, open-label trial compared intravenous (IV) lidocaine to lidocaine administered via bilateral continuous ESP blocks for analgesic efficacy in the context of open heart surgery. Seventy patients (18-80 years) undergoing primary single procedure elective cardiac surgery via midline sternotomy were randomized to receive lidocaine infusion via IV or continuous bilateral ESP block routes. The primary outcomes were cumulative opioid consumption in the first 48 h postoperatively (Oral Morphine milligram equivalents- OME) and pain scores at 48 h (Numeric Rating Scale NRS). Secondary outcomes included additional timepoints for pain and opioid consumption measures within the first 48 postoperative hours and plasma lidocaine levels at various timepoints within 24 h of initiating therapy. Sixty patients were analyzed after various exclusions. Both groups achieved acceptable analgesia, but the ESP group was not found to be superior to IV lidocaine in reducing opioid consumption in the first 48 hours (MD = -12.43 [95% CI, -43.7 to 18.8], p = 0.375) or pain scores at 48 h (MD 0.05 [95% CI, -1.7 to 1.8], p = 0.878). No significant differences were found in secondary outcomes. Plasma arterial lidocaine levels exceeded 5 μg/mL in 4 patients in the IV group and 2 in the ESP group at 24 h. ESP blocks utilizing lidocaine did not demonstrate superior postoperative analgesia compared to intravenous lidocaine in patients undergoing elective primary cardiac surgery via midline sternotomy. Safety concerns regarding systemic lidocaine accumulation from both administration routes warrant further evaluation.

Intravenous Lidocaine for the Management of Chronic Pain: A Narrative Review of Randomized Clinical Trials.

Onyeaka H, Adeola J, Xu R, Pappy AL, Adeola S , et al.
Psychopharmacology bulletin

Chronic pain remains a serious health problem with significant impact on morbidity and well-being. Available treatments have only resulted in relatively modest efficacy. Thus, novel therapeutic treatments with different mechanisms have recently generated empirical interest. Lidocaine is postulated to provide anti-inflammatory and anti-nociceptive effect through its action at the N-methyl-D-aspartate (NMDA) and voltage gated calcium receptors. Emerging research indicates that lidocaine could be a reasonable alternative for treating chronic pain. Considering the evidence surrounding lidocaine's potential as a therapeutic modality for chronic pain, we conducted a narrative review on the evidence of lidocaine's therapeutic effects in chronic pain. A review of the PubMed, and Google scholar databases was undertaken in May 2022 to identify completed studies that investigated the effectiveness of lidocaine in the treatment of chronic pain from database inception to June 2022. A total of 25 studies were included in the narrative review. Findings on available studies suggest that intravenous infusion of lidocaine is an emerging and promising option that may alleviate pain in some clinical populations. Our narrative synthesis showed that evidence for intravenous lidocaine is currently mixed for a variety of chronic pain syndromes. Findings indicate that evidence for efficacy is limited for: CRPS, and cancer pain. However, there is good evidence supporting the efficacy of intravenous lidocaine as augmentation in chronic post-surgical pain. Lidocaine may be a promising pharmacologic solution for chronic pain. Future investigation is warranted on elucidating the neurobiological mechanisms of lidocaine in attenuating pain signaling pathways.